Technology | Computed Tomography (CT) | December 07, 2018

FDA Approves New Features for Planmed Verity Cone Beam CT Scanner

Improvements include Ultra Low Dose imaging protocol and new algorithm for motion artifact correction

FDA Approves New Features for Planmed Verity Cone Beam CT Scanner

December 7, 2018 — The U.S. Food and Drug Administration (FDA) issued an approval letter for the new features and intended uses of the Planmed Verity cone beam computed tomography (CBCT) orthopedic imaging solution on Nov. 30, 2018.

The improved Planmed Verity now offers enhanced image quality as well as new options for head and neck imaging, the Planmeca Ultra Low Dose imaging protocol for lower patient doses, and Planmeca CALM algorithm for motion artifact correction.

The new enhancements include the iterative Planmeca CALM algorithm, which reduces artifacts caused by patient movement. The algorithm is especially useful in challenging weight-bearing examinations in which patients have a tendency to move. Meanwhile, the Planmeca Ultra Low Dose (ULD) imaging protocol enables reduction of already low effective patient doses even further, without compromising diagnostic image quality.

For more information: www.planmed.com

Related Content

Chief among the myriad practical updates to minimize risks for patients and imaging personnel alike is a tiered approach for delaying both outpatient and inpatient cross-sectional interventional procedures

For procedural delays that will not adversely affect patient outcome, Fananapazir and colleagues proposed the following tiered approach for both outpatient and inpatient scenarios: urgent procedures, procedures that should be performed within 2 weeks, procedures that should be performed within 2 months, and procedures that can safely be delayed 2 or 6 months. Courtesy of American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | June 05, 2020
June 5, 2020 — An...
AIR Recon DL delivers shorter scans and better image quality (Photo: Business Wire)

AIR Recon DL delivers shorter scans and better image quality (Photo: Business Wire).

News | Artificial Intelligence | May 29, 2020
May 29, 2020 — GE Healthcare announced U.S.
Largest case series (n=30) to date yields high frequency (77%) of negative chest CT findings among pediatric patients (10 months-18 years) with COVID-19, while also suggesting common findings in subset of children with positive CT findings

A and B, Unenhanced chest CT scans show minimal GGOs (right lower and left upper lobes) (arrows) and no consolidation. Only two lobes were affected, and CT findings were assigned CT severity score of 2. Image courtesy of American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | May 29, 2020
May 29, 2020 — An investigation published open-access in the ...
United Imaging's uMR OMEGA is designed to provide greater access to magnetic resonance imaging (MRI) with the world’s first ultra-wide 75-cm bore 3T MRI.
News | Magnetic Resonance Imaging (MRI) | May 27, 2020
May 27, 2020 — United Imaging's...
There were several new developments in digital radiography (DR) technology at the 2019 Radiological Society of North America (RSNA) annual meeting. These trends included integration of artificial intelligence (AI) auto detection technologies, more durable glassless detector plates, and technologies to pull more diagnostic data out of X-ray imaging. Some vendors also have redesigned their DR systems to make them more user-friendly and ergonomic. 
Feature | Digital Radiography (DR) | May 26, 2020 | By Dave Fornell
There were several new developments in digital rad...
The Breast Imaging and Reporting System (BI-RADS) was established by the American College of Radiology to help classify findings on mammography. Findings are classified based on the risk of breast cancer, with a BI-RADS 2 lesion being benign, or not cancerous, and BI-RADS 6 representing a lesion that is biopsy-proven to be malignant.

Getty Images

News | Breast Imaging | May 19, 2020
May 19, 2020 — Women with mammographically detected breast lesions that are probably benign should have follow-up sur